Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Flinders University, Australia

ESMO 33

12 - 16 Sep 2008

Published: 4 Dec 2008

Views: 14892

Rating:

Save

Dr. Christos Karapetis

Gene marker indicates doubling of survival time in cetuximab-treated CRC

Related Videos

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Bone disease evaluation of newly diagnosed MM with combined use of 18F-FDG PET/CT and whole-body diffusion weighted MRI ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Avelumab combined with regorafenib shows improved outcome in solid tumours with...

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )

Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria

Gastro-intestinal endoscopy capacity in Nigeria: strengths and challenges ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )

Colorectal cancer risk factors in Nigeria

Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria

Colorectal cancer risk factors in Nigeria ( Prof Olusegun Alatise - Obafemi Awolowo University, Ife, Nigeria )

Latest treatments in oesophageal cancer

Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA

Latest treatments in oesophageal cancer ( Dr Costas Bizekis - NYU Langone Perlmutter Cancer Center, New York, USA )

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates...

Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer ( Dr Stacey Cohen - Fred Hutchinson Cancer Center, Washington, USA )

An overview of treatment advances in gastric cancer

Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA

An overview of treatment advances in gastric cancer ( Prof David Ilson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Optimum treatment strategy algorithm for mCRC

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Optimum treatment strategy algorithm for mCRC ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

More from ecancer